Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial

Overview of attention for article published in Journal of Hematology & Oncology, March 2016

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 5,875 followers.

RT @FrancescoTurtu1: #endlymphoma Romidepsin for the treatment of RR-PTC #lymphoma: prolonged stable disease provides clinical benefits htt…

#endlymphoma Romidepsin for the treatment of RR-PTC #lymphoma: prolonged stable disease provides clinical benefits https://t.co/wQZGMKlH54

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.